Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 InferMed , ... will augment ... clinical s olutions suite   Elsevier ... products and services, announced today the acquisition of  InferMed , ... technology company. InferMed,s Arezzo technology supports clinicians in ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... take part in the first half of “Integrative Biotechnology,” an applied biotechnology course ... in summer 2014, this course combines students from both universities and is taught ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  Today, Americord ... the U.S., announced Andrew Horne , a partner at ... Advisory Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... appointment to Americord,s Advisory Board," says Martin Smithmyer , ... experience in his legal career that will assist Americord,s growth ...
(Date:6/30/2015)... ... ... Matrix Marketing Group, LLC , a leading provider of performance-based marketing ... its account management department as vice president of client services. Amanda Gregory joins ... and delivery expertise to the growing Matrix Marketing Group team in Denver, Colorado. ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Americord Registry Announces Andrew Horne as Advisory Board Member 2Matrix Marketing Group Expands Client Services Team 2
... Citing one-time gains due to Hurricane Katrina and other Gulf ... a net loss of nearly $45 million, or 20 cents ... information management services firm reported net income of $105.9 million, ... of 2005, a drop of 29.6 percent. , ,The decrease ...
... visit to the Menomonee Valley, Gov. Jim Doyle ... state budget for the new Wisconsin Venture Center. , ,Doyle ... that will connect entrepreneurs with sources of capital, and serve ... in Wisconsin. , ,The concept was announced in December of ...
... most spending proposals, the devil is in the details and ... Jim Doyle's new Grow Milwaukee package contains several initiatives ... ,The package, which Doyle alluded to in last week's ... economic development, healthcare, and education proposals designed to build on ...
Cached Biology Technology:Doyle proposes $2M for venture capital center 2Grow Milwaukee includes millions for tech funding 2Grow Milwaukee includes millions for tech funding 3
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... a 12-year action plan calling for reducing the hypoxia zone ... and there is no evidence that nutrient loading to the ... have identified some of the biophysical and social barriers to ... that a partnership of researchers work closely with farmers to ...
... N.H. A grant to the University of New ... biologists identify an abundant yet largely unknown category of ... functions they play. The National Science Foundation awarded ... Network on eukaryotic biodiversity. The work will apply new ...
... Md. (Nov. 7, 2013)Chronic obstructive pulmonary diseasea health problem ... it progressively harder to breathecan have a dramatic effect ... activities of daily life because of the disease,s fallout ... in these muscle problems. These include loss of fitness ...
Cached Biology News:Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3UNH, UC Davis launch network to study environmental microbes 2Vitamin C could ease muscle fatigue in chronic obstructive pulmonary disease patients 2
... S-X media are neutral, porous ... exclusion chromatography of lipophilic polymers ... organic eluents. The beads are ... carbon tetrachloride, dimethylformamide, ketones, aromatics, ...
... Anti-GSTM1 Monoclonal Antibody Epitope: ... [Schistosoma japonicum]. Recommended Storage: ... Aliquot contents and freeze at -20 C ... of freezing and thawing. Centrifuge product if ...
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
... unique aptamer microarray services using a ... and sequence design software to suit ... screening of aptamers as drug candidates. ... sequence design, synthesis of standard or ...
Biology Products: